

MSD in Switzerland. Inventing for life.

For more information about MSD in Switzerland:
www.msd.ch



Follow us on:



MSD Merck Sharp & Dohme AG, Werftstrasse 4, 6005 Lucerne, Switzerland.
Copyright © 2022 Merck & Co., Inc., Rahway, NJ, USA and its affiliates. All rights reserved.
CH-NON-01327, 05/2022



About MSD

For nearly 130 years, we have been addressing the world's major health challenges and providing hope in the fight against diseases, for both people and animals.

In Lucerne and in our newly opened hub in Zurich we bring creative minds together to transform world-class science into life-changing medicines and vaccines.



Oncology/
Immuno-Oncology



Vaccines



Infectious
Diseases



Diabetes



Immunology



Animal Health



Our Purpose:

We use the power of leading-edge science to save and improve lives around the world.

Our Aspiration:

We aspire to be the premier research-intensive biopharmaceutical company.

MSD in Switzerland

Facts and figures

1963 MSD in Switzerland established

~ 1,000 Employees from 56 nations

50 % Proportion of women

~ 35 Clinical studies per year

10× Top Employer Switzerland

5 Locations

Schachen

Global clinical supplies,
MRL (MSD Research Laboratories),
Forensic Laboratory

Zurich, The Circle

Global Innovation and
Development Hub

Kriens

International Business

Lucerne

Medical, Marketing, Finance

Animal Health,
Regional Finance, MMD
(MSD Manufacturing Division)


Our focus areas in Research & Development

The journey to invention and discovery is guided by science – and inspired by patients. Our purpose is to save and improve lives for generations. Our strategy is simple: We follow the science. In 2021 our company invested globally 12.2 billion US \$ in R&D. We are tireless in seeking solutions for some of the world's most pressing health challenges.



Cancer is one of the most significant health challenges facing our society

Innovation, affordability and equal access are our three priorities for improving cancer care in the future.




Breakthroughs in cancer therapies are offering cancer patients new hope regarding the management of their condition, quality of life and life expectancy, while offering healthcare providers the opportunity to achieve unprecedented outcomes for people living with cancer.

We aim to translate cutting-edge science into breakthrough oncology medicines. Our commitment to research and development has enabled us to establish an exceptionally broad clinical research program which is world leading.

We are collaborating with other pharmaceutical companies to develop the best therapeutic options to treat cancer. Swiss oncologists, researchers, nurses and patients make a significant contribution to this program, and MSD currently conducts over 35 clinical trials in more than 11 different tumor types in Switzerland. Today, our portfolio includes oncology medicines that treat many different cancers, and we are studying many more tumor types in various therapeutic settings.

We have a legacy in preventing disease through vaccines

Vaccines are one of the greatest public health success stories in history as they remain the most important preventive medical measure throughout life.



Dr. Maurice Hilleman played a pioneering role in the history of MSD. He developed more than 40 vaccines. Nine are part of the 14 essential childhood vaccines against Measles, Mumps, Rubella, Hepatitis A, Hepatitis B, Meningitis and Pneumococcal that have protected untold millions of children around the world from devastating diseases and early deaths.

Protection against infectious diseases is particularly important at the beginning of life. However, a life course approach to vaccinations remains essential, as vaccinating people across their lifetime may protect them and others from the changing epidemiology of infectious diseases.

While progress has been made in the fight against certain HPV-related diseases, we are continuing our work in eliminating HPV-related cancers, as they remain a significant public health burden for both women and men. In addition we continue to advance our efforts against Pneumococcal and other infectious diseases.






We've been combating global health threats caused by infectious diseases for more than a century. From developing one of the first antibiotics to pioneering HIV therapies, our focus has always been on the prevention and treatment of infectious diseases.

Since the beginning of the COVID-19 pandemic, MSD has been engaged in research and scientific discourse on the SARS-CoV-2 virus in order to help with finding solutions.

In the fight against infectious diseases, MSD sets focus on areas where there are still high unmet needs and where we can add the most value with our unique expertise and capabilities to advance our development programs against infectious diseases.



Infectious diseases such as COVID-19 and Ebola are a global health challenge and require global solutions




The Ebola virus has had a devastating impact on the world and has proved itself to be a deadly and extremely contagious disease. Along with international organizations and governments, MSD has played – and continues to play – a leadership role in responding to Ebola.

Diabetes

We are investigating the development of new treatment options to further improve the quality of life of diabetes patients. Our scientific efforts to profoundly understand type 2 diabetes persist. Diabetes is one of the fastest growing health challenges of the 21st century. Advancements in research have made an impactful difference for patients, and there is still much more work to be done. We strive for scientific excellence and innovation in all stages of research, from discovery through approval and beyond.

Immunology

Our immunology portfolio is well anchored by a broad range of therapies against inflammatory diseases. In addition, we are developing novel therapeutics designed to address the unmet needs of patients living with autoimmune diseases.



MSD Animal Health, one of the leading research companies in veterinary medicine

MSD supports the precious bond between people and their pets.



MSD Animal Health develops and markets products for the prevention, treatment, and control of diseases in farm animals and pets. With the most innovative and largest product portfolio for animal health in Switzerland, MSD contributes substantially to animals' well-being.



Following our founder's vision


1894, George W. Merck started to run the company his father founded. His entrepreneurial compass focused on: courage, believing in science and the vision to provide medicines to those who need.



MSD has been working to invent and improve health-care for over a century. When George W. Merck's father founded the company in 1891, his goal was to manufacture standardized and thus safer medicines and distribute them to those who need.



Today our company creates innovative medicines that help millions of people around the world. Our company is present in 140 countries and represented by around 68,000 passionate employees.



Our values and culture

At MSD Switzerland, “Diversity and Inclusion” is part of our DNA. We strive to create an environment with the highest standards of ethics and integrity for the customers we serve, the people we support worldwide and the eco-system we inhabit.

Being awarded once more as Top Employer Switzerland and Europe is a powerful testimonial to our unwavering commitment to providing our employees with the best possible working environment in which they can learn, grow and thrive.

As a forward looking employer, our “New Ways of Working” initiative encompasses more than the use of new technologies and flexible workplace; it includes closing of gaps between generations by knowledge sharing, enabling to see the value of change and adoption of agile working methods.

A recent highlight of our pioneering role in closing gender gaps is the gender-neutral parental leave of 16 weeks for all parents. It is our employees’ know-ledge, imagination and skills which drive our innovations. We believe they are the core of our success.



Join us:
jobs.msd.com/switzerland



Social responsibility

We keep our promise to fulfill our social responsibility.
In Switzerland and worldwide.

Operating responsibly is fundamental to our long-term success, to our obligation to society and to the health and well-being of patients and our employees. We consciously meet our social responsibility towards society. In doing so, we are guided by our mission statement: to discover, develop and provide innovative products and services to save and improve lives.



Responding to the SARS-CoV-2 pandemic

Demonstrating our legacy of good corporate citizenship we support communities in pandemic advisory, testing and vaccination centers and vaccine administration. We support other pharmaceutical companies in the production of vaccines without neglecting our own research and development of therapies against the lung disease and ensure that patients who need our other medicines continue to receive them.

Our engagements with partners

HPV Alliance

Roundtable Antibiotics

Health Literacy Alliance

Corporate Volunteering

Trendtage Gesundheit Luzern

Allianz Q



We create sustainable value

Our main contribution to society is improving healthcare, developing better medicines and grant access to all who need.

Our footprint in Switzerland is growing, as is our responsibility to the municipalities and cantons. We continue to focus on the development of therapies with high unmet medical need and our commitment to work together with all stakeholders to enable access for all people who need our products.

Environment

The environment needs our protection. Our ambitious goal is to achieve carbon neutrality across our operations by 2025 and a 30 % reduction in our value chain emissions by 2030.

